Our findings revealed the following key insights: (1) RC48 demonstrated favorable efficacy and manageable safety in patients with advanced or metastatic BC, particularly showing superior efficacy in patients with HER2-positive BC compared to those with HER2-low-expression. The gene discussed is ERBB2; the disease is breast cancer.